Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer.

Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K, Japanese Society for Cancer of the Colon and Rectum. · 2015

Read Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. by Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K, Japanese Society for Cancer of the Colon and Rectum. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4653248.txt.

Introduction

Toshiaki Watanabe and colleagues published the 2015 English version of the Japanese Society for Cancer of the Colon and Rectum guidelines for colorectal cancer treatment. Colorectal cancer is the leading cancer killer of women in Japan and the third among men. Many new treatments had appeared in recent decades. The guidelines appeared in the International Journal of Clinical Oncology.

A guideline committee reviewed the evidence and debated contested questions, grading both evidence strength and recommendation strength for each answer. The aims were to cut treatment gaps between hospitals, avoid both needless and insufficient treatment, and help clinicians and patients understand each other. Because the guidance weighs Japan's insurance system and real practice, it serves as a bedside reference for consent talks and for choosing each patient's treatment.

Catalog record

CREATORWatanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K, Japanese Society for Cancer of the Colon and Rectum.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE110 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4653248

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer By Toshiaki Watanabe, Michio Itabashi, Yasuhiro Shimada, Shinji Tanaka, Yoshinori Ito, Yoichi Ajioka, Tetsuya Hamaguchi, Ichinosuke Hyodo, Masahiro Igarashi, Hideyuki Ishida, Soichiro Ishihara, Megumi Ishiguro Published in: International Journal of Clinical Oncology DOI: 10.1007/s10147-015-0801-z ABSTRACT Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms among women and the third largest number among men. Many new methods of treatment have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2014 for treatment of colorectal cancer (JSCCR Guidelines 2014) have been prepared as standard treatment strategies for colorectal cancer, to eliminate treatment disparities among institutions, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding among health-care professionals and patients by making these guidelines available to the general public. These guidelines have been prepared as a result of consensuses reached by the JSCCR Guideline Committee on the basis of careful review of evidence retrieved by literature searches and taking into consideration the medical health insurance system and actual clinical practice in Japan. They can, therefore, be used as a guide for treating colorectal cancer in clinical practice. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions of the Guideline Committee, controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories, on the basis of consensus reached by Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2014. INTRODUCTION 1. Guideline objectives The incidence and mortality of colorectal cancer have substantially increased in Japan recently. According to vital statistics for Japan in 2012, colorectal cancer accounted for the largest number of deaths from malignant neoplasms among women and the third largest number among men, after lung cancer and gastric cancer. The number of deaths from colorectal cancer per unit population has increased approximately tenfold during the past 50 years. Many new treatment methods have been developed during that time, and their use in combination with advances in diagnostic methods has led to a steady improvement in the results of treatment. However, different treatment is used among medical institutions in Japan that provide medical care for patients with colorectal cancer, and the differences may lead to differences in the results of treatment. In such circumstances, the JSCCR Guidelines 2014 for treatment of colorectal cancer, which are intended for doctors (general practitioners and specialists) who provide medical care for patients with colorectal cancer in different disease stages and conditions, have been prepared for four purposes: to disseminate standard treatment strategies for colorectal cancer;to eliminate disparities among institutions in terms of treatment;to eliminate unnecessary treatment and insufficient treatment; andto deepen mutual understanding among health-care professionals and patients by making these guidelines available to the general public [1]. Achievements expected as a result of these guidelines are: improvement of treatment of colorectal cancer in Japan;improvement of the results of treatment;reduction of human and financial burden; andincreased benefits for patients. 2. How to use these guidelines These guidelines have been as a result of consensuses reached by the Guideline Committee of the Japanese Society for Cancer of the Colon and Rectum, on the basis of careful review of evidence retrieved by literature searches and taking into consideration the medical health insurance system and clinical practice in Japan. They can, therefore, be used as a guide for treating colorectal cancer in clinical practice. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. However, these guidelines provide only general recommendations for choosing treatment strategies for colorectal cancer, and they do not control or limit treatment strategies or treatment methods that are not described herein. These guidelines can also be used as a document to explain the rationale for selecting treatment strategies and treatment methods that differ from those described in the guidelines. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) is responsible for the statements in these guidelines. However, the personnel directly in charge of treatment, not the JSCCR or the Guideline Committee, are responsible for the outcome of treatment. 3. Users The users of these guidelines are mainly clinical doctors engaged in all aspects of the medical treatment of colorectal cancer. 4. How to develop these guidelines 1) Recording methods We adopted the concept from the first edition in which the treatment policy algorithm was disclosed and a simple explanation thereof provided, and added further comments with regard to categories requiring additional explanation. Since the 2009 edition, topics of debate have been raised as clinical questions (CQs) and included with recommendations added. In the 2014 edition, this practice was continued, with corrections and additions made to the CQs on the basis of knowledge acquired since the 2010 version. 2) Evidence level and strength of recommendations of CQs The recommendations added to CQs included the evidence level and the strength of recommendations determined by use of the following guidance. 2-1) Evidence level Papers relating to the CQs were comprehensively collected and evidence in individual papers relating to critical outcomes included in the CQs was divided into groups by study design [2]. The literature level and the body of evidence (Table 1) were evaluated with reference to the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) system [3–25], before determining the final CQ evidence level (Table 2).Table 1Rating the quality of evidenceStep 1 (evaluation of individual study): study design, evaluation of bias risk, create structured abstractStep 2 (overall rating for each important outcome across studies):1. Initial quality of a body of evidence: evaluation of each study design group ・Systematic reviews, meta-analysis, randomized controlled trials = “initial quality A (high level)” ・Observation studies, cohort studies, case control studies = “initial quality C (low level)” ・Case series, case reports = “initial quality D (very low level)”2. Five possible reasons for downrating the quality ・Risk of bias ・Inconsistency in results ・Indirectness of evidence ・Data imprecision ・High possibility of publication bias3. Three possible reasons for uprating the quality ・Large effect with no confounding factors ・Dose–response gradient ・Possible confounding factors are weaker than actual effects4. We evaluate 1->2->3, and assess the quality of a body of evidenceTable 2Definition of levels of evidence [13]A (high):We are very confident in the estimate of the effectB (moderate):We are moderately confident in the estimate of the effect: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially differentC (low):Our confidence in the estimate of the effect is limited: the true effect may be substantially different from the estimate of the effectD (very low):We have very little confidence in the estimate of the effect: the true effect is likely to be substantially different from the estimate of effect 2-2) Strength of recommendations Draft recommendation statements and the strength of the recommendations were based on outcomes and the level of

Read the complete text